Novo Nordisk announced on 14 April 2026 a strategic partnership with OpenAI to streamline the business, from drug discovery to commercial operations.
Accelerating drug development
The Danish drugmaker will leverage OpenAI’s artificial intelligence technology to analyse complex datasets, identify promising drug candidates and streamline manufacturing, supply chains and distribution.
Mike Doustdar, President and CEO, Novo Nordisk, said: “This partnership is one important step in positioning Novo Nordisk to lead in the next era of healthcare.
“There are millions of people living with obesity and diabetes who need treatment options, and we know there are therapies still waiting to be discovered that could change their lives.
“Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever.
“This means discovering new therapies and bringing them to market faster than ever before.”
Upskilling the workforce
Alongside improving efficiency in drug development processes, Novo will reportedly employ OpenAI’s technology to upskill the workforce and enhance AI literacy.
Sam Altman, CEO, OpenAI, said: “AI is reshaping industries and in life sciences, it can help people live better, longer lives.
“This collaboration with Novo Nordisk will help them accelerate scientific discovery, run smarter global operations and redefine the future of patient care.”
Plans for full integration
The move builds on Novo’s existing AI initiatives, which include collaboration with varied technology partners and research organisations.
Drugmakers are increasingly turning to AI to optimise aspects of the development process, such as helping find participants and sites for clinical trials and drafting documents.
Novo reported that the partnership has been structured with strict data protection, governance and human oversight to ensure ethical compliance and use.
Pilot programmes are set to launch across research and development, manufacturing and commercial operations, with full integration by the end of 2026.
Featured image: AdriaVidal on Adobe Stock
